1. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
- Author
-
Kiso, Maki, Yamayoshi, Seiya, Furusawa, Yuri, Imai, Masaki, and Kawaoka, Yoshihiro
- Subjects
- *
INFLUENZA A virus, H7N9 subtype , *AVIAN influenza A virus , *AVIAN influenza , *RESPIRATORY organs , *TREATMENT effectiveness , *VIRUS diseases - Abstract
Viral neuraminidase inhibitors show limited efficacy in mice infected with H7N9 influenza A viruses isolated from humans. Although baloxavir marboxil protected mice from lethal challenge infection with a low pathogenic avian influenza H7N9 virus isolated from a human, its efficacy in mice infected with a recent highly pathogenic version of H7N9 human isolates is unknown. Here, we examined the efficacy of baloxavir marboxil in mice infected with a highly pathogenic human H7N9 virus, A/Guangdong/17SF003/2016. Treatment of infected mice with a single 1.5 mg/kg dose of baloxavir marboxil protected mice from the highly pathogenic human H7N9 virus infection as effectively as oseltamivir treatment at 50 mg/kg twice a day for five days. Daily treatment for five days at 15 or 50 mg/kg of baloxavir marboxil showed superior therapeutic efficacy, largely preventing virus replication in respiratory organs. These results indicate that baloxavir marboxil is a valuable candidate treatment for human patients suffering from highly pathogenic H7N9 virus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF